Stock listing
NASDAQ:LBRX LB Pharmaceuticals Inc Stock
Home listing (NASDAQ) of LB Pharmaceuticals Inc
Follow LB Pharmaceuticals Inc into a list and get an email when it puts out news.
Share price · NASDAQ:LBRX
$40.06 USD -0.24 (-0.6%)
Close on Nov 18, 2026
- Day range
- $38.72 – $41.71 USDNov 18, 2026
- Volume
- 356,411 sharesNov 18, 2026
- Market cap
- $1.30B USDAt the close on Nov 18, 2026 · price × 32.36M shares outstanding
- 52-week range
- $15.19 – $50.16 USDLowest and highest trades, Nov 19, 2025 – Nov 18, 2026
- Traded on an average day
- $15.07M USDMedian day 355,391 shares · last 3 months, Aug 18, 2026 – Nov 18, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LBRX · Home | $40.06 USD | -0.24 (-0.6%) | 356,411 | $40.31 | $41.71 | $38.72 | $40.30 | Close on Nov 18, 2026 |
Daily closes
Last 3 months, Aug 18, 2026 – Nov 18, 2026 · NASDAQ:LBRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $40.06 | -0.24 | -0.6% | $40.31 | $41.71 | $38.72 | 356,411 | |
| $40.30 | -2.69 | -6.3% | $43.20 | $44.01 | $38.83 | 396,092 | |
| $42.99 | -0.02 | 0.0% | $43.07 | $43.95 | $42.08 | 597,257 | |
| $43.01 | +0.55 | +1.3% | $42.66 | $43.43 | $41.03 | 330,168 | |
| $42.46 | -2.25 | -5.0% | $44.37 | $44.37 | $41.88 | 438,110 | |
| $44.71 | -0.23 | -0.5% | $45.21 | $45.46 | $44.30 | 341,759 | |
| $44.94 | -0.18 | -0.4% | $44.38 | $45.68 | $43.46 | 377,881 | |
| $45.12 | +3.11 | +7.4% | $43.05 | $45.77 | $41.54 | 472,299 | |
| $42.01 | +3.92 | +10.3% | $38.53 | $42.29 | $38.52 | 476,193 | |
| $38.09 | -2.76 | -6.8% | $41.01 | $41.01 | $38.02 | 354,370 | |
| $40.85 | +0.52 | +1.3% | $41.40 | $41.40 | $38.75 | 365,762 | |
| $40.33 | +1.29 | +3.3% | $39.65 | $41.40 | $39.15 | 245,821 | |
| $39.04 | -0.66 | -1.7% | $40.56 | $40.91 | $38.24 | 466,446 | |
| $39.70 | -0.45 | -1.1% | $40.10 | $41.24 | $39.13 | 429,435 | |
| $40.15 | +0.32 | +0.8% | $39.80 | $40.76 | $39.23 | 400,678 | |
| $39.83 | +0.19 | +0.5% | $39.53 | $40.38 | $38.49 | 201,736 | |
| $39.64 | +0.30 | +0.8% | $39.14 | $40.35 | $38.58 | 236,345 | |
| $39.34 | +0.61 | +1.6% | $41.05 | $41.05 | $38.45 | 275,975 | |
| $38.73 | -0.69 | -1.8% | $39.25 | $39.73 | $38.26 | 188,600 | |
| $39.42 | +0.19 | +0.5% | $39.12 | $41.58 | $38.39 | 230,900 | |
| $39.23 | -1.77 | -4.3% | $41.10 | $41.24 | $39.04 | 247,100 | |
| $41.00 | +2.19 | +5.6% | $38.88 | $41.42 | $38.24 | 388,400 | |
| $38.81 | +2.07 | +5.6% | $36.91 | $40.10 | $36.03 | 588,500 | |
| $36.74 | +0.05 | +0.1% | $36.62 | $37.37 | $36.06 | 724,700 | |
| $36.69 | +2.69 | +7.9% | $34.54 | $37.43 | $34.50 | 976,600 | |
| $34.00 | -0.79 | -2.3% | $34.10 | $35.51 | $33.88 | 362,700 | |
| $34.79 | -1.14 | -3.2% | $36.10 | $36.10 | $34.44 | 296,800 | |
| $35.93 | -1.29 | -3.5% | $37.26 | $37.43 | $34.54 | 491,500 | |
| $37.22 | +2.61 | +7.5% | $35.01 | $38.50 | $35.01 | 642,600 | |
| $34.61 | +0.45 | +1.3% | $33.83 | $35.73 | $33.13 | 440,700 | |
| $34.16 | -0.10 | -0.3% | $34.02 | $36.57 | $34.00 | 385,000 | |
| $34.26 | -0.36 | -1.0% | $35.25 | $35.59 | $33.73 | 432,800 | |
| $34.62 | -2.37 | -6.4% | $36.41 | $36.88 | $34.47 | 494,500 | |
| $36.99 | -0.29 | -0.8% | $37.72 | $38.82 | $36.75 | 388,900 | |
| $37.28 | -1.10 | -2.9% | $38.10 | $38.59 | $37.13 | 278,900 | |
| $38.38 | +1.10 | +3.0% | $37.61 | $39.23 | $37.34 | 437,200 | |
| $37.28 | -0.61 | -1.6% | $37.89 | $38.13 | $36.98 | 713,400 | |
| $37.89 | +0.56 | +1.5% | $37.24 | $38.17 | $36.57 | 534,600 | |
| $37.33 | -0.47 | -1.2% | $37.85 | $38.57 | $36.99 | 398,900 | |
| $37.80 | -1.39 | -3.5% | $39.13 | $39.39 | $37.56 | 413,500 | |
| $39.19 | -3.50 | -8.2% | $42.80 | $42.80 | $38.84 | 481,700 | |
| $42.69 | -0.30 | -0.7% | $43.40 | $43.40 | $41.21 | 244,400 | |
| $42.99 | +0.52 | +1.2% | $42.55 | $43.22 | $41.54 | 310,200 | |
| $42.47 | +0.33 | +0.8% | $42.22 | $42.54 | $41.39 | 531,600 | |
| $42.14 | -0.43 | -1.0% | $43.33 | $43.50 | $41.78 | 314,500 | |
| $42.57 | -0.47 | -1.1% | $43.37 | $43.94 | $42.17 | 231,900 | |
| $43.04 | -1.80 | -4.0% | $44.84 | $44.84 | $42.50 | 320,500 | |
| $44.84 | +0.21 | +0.5% | $44.95 | $45.72 | $44.55 | 242,800 | |
| $44.63 | -1.62 | -3.5% | $46.80 | $47.68 | $44.40 | 208,400 | |
| $46.25 | -1.42 | -3.0% | $47.20 | $47.20 | $45.50 | 174,800 | |
| $47.67 | -1.72 | -3.5% | $49.07 | $49.81 | $47.46 | 190,100 | |
| $49.39 | +0.05 | +0.1% | $48.53 | $49.62 | $47.15 | 301,000 | |
| $49.34 | +1.82 | +3.8% | $47.47 | $49.91 | $47.47 | 206,000 | |
| $47.52 | -1.96 | -4.0% | $48.88 | $48.91 | $46.72 | 282,500 | |
| $49.48 | +2.38 | +5.1% | $47.31 | $49.93 | $46.44 | 518,400 | |
| $47.10 | -0.16 | -0.3% | $47.21 | $48.21 | $46.92 | 202,000 | |
| $47.26 | -0.47 | -1.0% | $47.47 | $47.50 | $46.38 | 386,900 | |
| $47.73 | -0.16 | -0.3% | $47.64 | $49.25 | $46.37 | 230,600 | |
| $47.89 | -0.275 | -0.6% | $48.15 | $48.42 | $47.14 | 256,100 | |
| $48.17 | -0.635 | -1.3% | $48.71 | $48.71 | $47.21 | 244,900 | |
| $48.80 | +0.59 | +1.2% | $48.70 | $50.16 | $48.49 | 217,000 | |
| $48.21 | +0.59 | +1.2% | $47.88 | $49.06 | $46.83 | 252,700 | |
| $47.62 | +0.39 | +0.8% | $47.71 | $48.21 | $46.34 | 225,800 | |
| $47.23 | -1.71 | -3.5% | $48.51 | $48.86 | $46.90 | 194,500 | |
| $48.94 | +0.17 | +0.3% | $49.80 | $49.97 | $48.24 | 162,200 | |
| $48.77 | +2.54 | +5.5% | $45.69 | $48.93 | $45.69 | 540,300 |
- Ticker
- NASDAQ:LBRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · Nov 5, 2026
Investor Presentation (November 2026)
Investor deck · 35 slides
Latest news
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026
Closed $42.01 (+10.3%) on Nov 6, 2026
LB Pharmaceuticals to Participate in Upcoming Investor Events
Oct 15, 2026
Closed $36.74 (+0.1%) on Oct 16, 2026
LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
Oct 10, 2026
Closed $35.93 (-3.5%) on Oct 12, 2026
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Oct 9, 2026
Closed $35.93 (-3.5%) on Oct 12, 2026
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
Oct 6, 2026
Closed $34.26 (-1.0%) on Oct 6, 2026
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
Sep 15, 2026
Closed $43.04 (-4.0%) on Sep 15, 2026
LB Pharmaceuticals to Participate in Upcoming September Investor Events
Sep 3, 2026
Closed $49.34 (+3.8%) on Sep 4, 2026
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
Sep 3, 2026
Closed $47.52 (-4.0%) on Sep 3, 2026
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 11, 2026
Closed $45.33 (-1.1%) on Aug 11, 2026
LB Pharmaceuticals Announces $150 Million Private Placement
Jul 29, 2026
Closed $39.00 (+11.6%) on Jul 29, 2026
Financings
Private placement of common stock and pre-funded warrants
Jul 29, 2026
Announced: about US$150M · US$34.94 a share · Leerink Partners +1
Dealers: Leerink Partners, Piper Sandler
Buyers: Adage Capital Partners, L.P.; BB Biotech; Caligan Partners; Commodore Capital; Deep Track Capital; Farallon Capital Management; Integral Health Asset Management; Janus Henderson Investors; Spruce Street Capital; StemPoint Capital LP
Use of proceeds: Expand LB-102 into new indications such as negative symptoms of schizophrenia and Alzheimer's agitation/psychosis, plus working capital and general purposes
Private placement of common stock and pre-funded warrants
Feb 5, 2026
Announced: about US$100M · US$21.17 a share · Leerink Partners +2
Dealers: Leerink Partners, Piper Sandler, Stifel
Buyers: Balyasny Asset Management L.P.; Caligan Partners; Commodore Capital; Deep Track Capital; Nantahala Capital; Pivotal bioVenture Partners; Spruce Street Capital; TCGX; Trails Edge Capital Partners
Use of proceeds: Fund a Phase 2 trial of LB-102 as adjunctive treatment for major depressive disorder, plus working capital and general corporate purposes
Public offering of common stock
Sep 11, 2025
Announced: US$285M · US$15 a share · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Stifel (co-lead)
Decks
Investor Presentation (November 2026)
Investor deck · 35 slides · Nov 5, 2026
Investor Presentation (October 2026)
Investor deck · 35 slides · Oct 27, 2026
Investor Day (October 2026)
Investor day · 60 slides · Oct 27, 2026
Investor Presentation (August 2026)
Investor deck · 35 slides · Aug 11, 2026
LB Pharmaceuticals Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 29 in the last 12 months · 36 in all · newest Nov 5, 2026 · oldest 2025
- Decks
- 16 decks · latest Nov 5, 2026
Where LB Pharmaceuticals Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LBRX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LBRX | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about LB Pharmaceuticals Inc.